Last reviewed · How we verify
Low Heparin Molecular Weight
Low molecular weight heparin (LMWH) inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.
Low molecular weight heparin (LMWH) inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome anticoagulation.
At a glance
| Generic name | Low Heparin Molecular Weight |
|---|---|
| Sponsor | University Hospital, Angers |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect inhibitor of Factor Xa and Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
LMWH is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in shorter chain lengths. This modification provides more predictable pharmacokinetics and preferential anti-Xa activity over anti-IIa activity compared to unfractionated heparin. LMWH is used for thromboprophylaxis and treatment of thromboembolic disorders.
Approved indications
- Venous thromboembolism prophylaxis
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome anticoagulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
- Osteoporosis (with prolonged use)
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (NA)
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- The Intensive Care Platform Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Heparin Molecular Weight CI brief — competitive landscape report
- Low Heparin Molecular Weight updates RSS · CI watch RSS
- University Hospital, Angers portfolio CI